Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-02
2006-05-02
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07037888
ABSTRACT:
The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
REFERENCES:
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5602096 (1997-02-01), Goodearl
patent: 6444642 (2002-09-01), Sklar et al.
patent: 6635249 (2003-10-01), Marchionni et al.
patent: PCT/US89/00051 (1989-07-01), None
patent: PCT/US90/02697 (1990-11-01), None
patent: PCT/US91/02331 (1991-10-01), None
patent: PCT/US91/03443 (1991-12-01), None
patent: PCT/US92/00329 (1992-07-01), None
Falls et al. Cell 72,801-815, 1993.
Marchionni et al. Nature 362, 312-318, 1993.
Benveniste et al., “Purification and characterization of a human T-Lymphocyte-derived glial growth-promoting factor”, Proc. Nat'l. Acad. Sci. USA 82:3930-3934, 1985.
Berger et al., “Correlation of c-erb8-2 gene amplification and protein expression in human breast carcinoma with . . . ” Cancer Research 48:1238-1243, 1988.
Brockes et al., “Purification and preliminary characterization of a glial growth factor from the bovine pituitary”, J. Biol. Chem. 255:8374-8377, 1980.
Brockes et al., “The neuron as a source of mitogen”, Development in the Nervous System, Garrod and Feldman, eds., pp. 309-327, 1980.
Chan et al., “Identification of a competative HGF antagonist encoded by an alternative transcript”, Science 254:1382-1385, 1991.
Davis et al., “Platelet-derived growth factors and fibroblast growth factors are mitogens for rat schwaan cells”, J. Cell. Biol. 110:1353-1360, 1990.
Davis et al., “Isolation and characterization of a new protein-specific activating factor from human ATL-2 cell conditioned medium”, Biochem. Biophys. Res. Comm. 179:1536-1542, 1991.
Dobashi et al., “Characterization of a neu/c-erbB-2 protein-specific activating factor”, Proc. Nat'l. Acad. Sci. USA 88:8582-8586, 1991.
Holmes et al., “Identification of Heregulin, a specific activator of p185erbB2” Science 256:1205-1210, 1992.
Huang et al., “Purification and characterization of the neu/erb B2 ligand-growth factor from bovine kidney” J. Biol. Chem. 267:11508-11512, 1992.
Kimura et al., “Structure, expression and function of a schwannoma-derived growth factor” Nature 348:257-260, 1990.
Kraus et al., “Overexpresssion of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms”, EMMBO J. 6:605-610, 1987.
Lemke et al., “Identification and purification of glial growth factor”, J. Neuroscience 4:75-83, 1984.
Lemke et al., “An immunochemical approach to the purification and characterization of glial growth factor”, Monoclonal Antibodies to Neural Antigens, McKay et al., eds. pp. 133-140, 1981.
Lupu et al., “Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185 erb2”, Science 249:1552-1555, 1990.
Lupu et al., “Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses”, Proc. Nat'l. Acad. Sci. USA 89:2287-2291, 1992.
Marchioni et al., “Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system”, Nature 362:312-362, 1993.
Peles et al., “Isolation of the new/HER-2 stimulatory ligand: . . . ”, Cell 69:205-216, 1992.
Peles et al., “Neu and its ligands: From an oncogene to neural factors”, Bioassays 15:815-824, 1993.
Perantoni et al., “Activated new oncogene sequences in primary tumors of the peripheral nervous system induced in rats . . . ”, Proc. Nat'l. Acad. Sci. USA 84:6317-6321, 1987.
Slamon et al., “Human breast cancer: Correlation of relapse and survival with amplification of the HER-2
eu oncogene”, Science 235:177-182, 1987.
Slamon et al., “Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer”, Science 244:707-712, 1989.
Tarakhovsky et al., “A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages”, Oncogene 6:2187-2196, 1991.
Tsuda et al., “Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: . . . ”, Cancer Research 49:3104-3108, 1989.
van de Vijver et al., “Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often . . . ”, Mol. Cell. Biol. 7:2019-2023, 1987.
Varley et al., “Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis”, Oncogene 1:423-430, 1987.
Venter et al., “Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlates with gene amplification”, II:69-72, 1987.
Wen et al., “Neu differentiation factor: A transmembrane clycoprotein containing an EGF domain and an immunoglobulin homology unit” Cell 69:559-572, 1992.
Yarden et al., “Biochemical analysis of the ligand for the neu oncogenic receptor” Biochemistry 30:3543-3550, 1991.
Yu et al., “Growth factor receptor tyrosine kinase”, Ann. Rev. Biochem. 57:443-478, 1988.
Zhou et al., “Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer”, Cancer Research 47:6123-6125, 1987.
Brockes et al., “Assay and isolation of glial growth factor from the bovine pituitary”, Methods in Enzym.
Jeong et al., Dialog Medline Abstract, J. Neurobiol. 22:462-74, 1991.
Jessel et al., “Induction of acetylcholine receptors on cultured skeletal muscle by a factor extracted from brain and spinal cord”, Proc. Nat'l. Acad. Sci. USA 76:5397-5401, 1979.
Lentz et al., “Partial purification and characterization of a nerve trophic factor regulating muscle acetylcholinesterase activity”, Exper. Neurology 73:542-557, 1981.
Markelonis et al., “Purification of sciatin using affinity chromatography on concanavalin in in A-agarose”, J. Neurochemistry 37:95-99, 1981.
Markelonis et al., Dialog Medline Abstract, J. Cell. Biol. 100:8-17, 1985.
Markelonis et al., Dialog Medline Abstract, J. Biol. Chem. 255:8967-70, 1980.
Markelonis et al., Dialog Medline Abstract, Exp. Neurol. 58:285-95, 1978.
Oh, “Neurotrophic effects of sciatic nerve extracts on muscle development in culture”, Exp. Neurol. 50:376-386, 1976.
Oh et al., Dialog Medline Abstract, Dev. Biology 127:88-98, 1988.
Oh et al., Dialog Medline Abstract, J. Neuros. Res. 8:535-45, 1982.
Oh et al., Dialog Medline Absrtact, Exp. Neurol. 67:646-54, 1980.
Oh et al., Dialog Medline Abstract, Science 200:337-9, 1978.
Oh et al., Dialog Medline Abstract, Exp. Neurol. 46:432-8, 1975.
Podleski et al., “Nerve extract induces increase and redistribution of acetylcholine receptors on cloned muscle cells”, Proc. Nat'l. Acad. Sci. USA 75:2035-2039, 1978.
Thibault et al., “Trophic effect of a sciatic nerve extract on fast and slow myosin heavy chain synthesis”, Am. Physiological Society 0363/6143; c269-c272, 1981.
Markelonis et al., Dialog Medline, J. Neurochem. 39:315-20, 1982.
Markelonis et al., Dialog Medline, Dev. Biol. 89:353-61, 1982.
Markelonis et al., Dialog Medline, J. Neurochem. 37:95-9, 1981.
Markelonis et al., Dialog Medline, Exp. Neurol. 70:598-612, 1980.
Oh et al., Dialog Medline, J. Histochem. Chytochem. 29:1205-12, 1981.
Oh et al., Dialog Medline, Proc. Nat'l. Acad. Sci. USA 77:6922-5, 1980.
Falls et al., “AIRA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family” Cell 72:810-815, 1993.
Florini et al., “Effects of
Gwynne David I.
Marchionni Mark
Sklar Robert
Acorda Therapeutics, Inc.
Pak Michael
LandOfFree
Methods for treating muscle diseases and disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating muscle diseases and disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating muscle diseases and disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3559254